Clinical Trials Service

Home Team Members Patient Information Clinical Trials Basic Research Fellowship Program Images of Omaha Contact Us: Division of Allergy and Immunology CreightonUniversity 601 North 30th Street, Suite 3M-100 Omaha,NE 68131 Ph.402.280.5975 Fx.402.280.5961 Email

The Center is conducting the following new and exciting studies. If you or someone you know is eligible and interested, we would love to hear from you.  Please call (402) 280-5975. Patient Demographics       The Omaha area has a population of over 750,000. The Division’s clinical research patient database alone is currently comprised of over 5,000 patients and is constantly growing through the various recruitment efforts including media advertising, health fair involvement as well as volunteer work. Our diverse patient population is drawn not only from the Omaha metropolitan area (urban/suburban), but also from the surrounding communities in Eastern Nebraska and Western Iowa (rural). Areas of Research Acute and chronic otitis media Acute and chronic urticaria Acute sinusitis Allergic asthma Allergic bronchopulmonary aspergillosis Allergic conjunctivitis Angioedema Asthma in pregnancy B cell immunodeficiencies Bronchitis Common variable immunodeficiency Contact dermatitis Drug allergy Exercise induced asthma Food allergy and food hypersensitivity Immunizations and immunoprophylaxis Insect allergy Latex allergy Management of immunotherapy Non-allergic asthma Nasal polyposis  Perennial allergic rhinitis  Seasonal allergic rhinitis  Status asthmaticus  T-cell immunodeficiencies  Vasomotor rhinitis Urticaria      The Division of Allergy and Immunology has a three bed inpatient unit suitable for Phase I and Phase II studies.  The Division conducts first-in-man studies and has several model systems for proof of concept trials for allergic and respiratory diseases. In addition, the basic research laboratories of the Division are capable of assisting in clinical trials with the measurement of biomarkers and mechanistic assays.  Procedures and Equipment Available Acoustic Rhinometry Aeroallergen challenge Exercise challenge Hypertonic Saline challenge Methacholine challenge Bronchoprovocation Challenges Biomarker Assays (Interleukins/Cytokines, Leukotrienes, Histamine, Tryptase, ECP)                  Digital Electrocardiography Machine Full Pulmonary Function Laboratory Immediate and Delayed Hypersensitivity Skin Testing Immunotherapy Inpatient Beds Nasal Allergen Challenges and Lavage Nitric Oxide Measurements (oral/nasal) Oral Desensitization Parenteral Therapy Facilities Phlebotomy Pollen Collection Radiology Suite for Routine X-Rays, MRIs ,CTs, Nuclear Studies Remote Data Entry Capabilities Spirometry Sputum Induction Treadmill Exercise Testing Investigators Thomas B. Casale, M.D. Professor of Medicine and Medical Microbiology & Immunology; Chief, Division of Allergy & Immunology Bio Robert G. Townley, M.D. Professor of Medicine and Medical Microbiology & Immunology Bio Againdra K. Bewtra, M.B.B.S., M.D. Associate Professor of Medicine & Biomedical Sciences Bio Jeffrey R. Stokes, M.D. Associate Professor of Medicine, Fellowship Program Director, Fellowship Program     Bio Russell J. Hopp, D.O. Professor of Pediatrics and Medicine; Chief, Division of Pediatric Allergy & Clinical Immunology Bio  Staff Patrick De Nier:  Operations Manager Tony Tony Romero, MS:  Budget, Contracts, & Regulatory Documents Dian Jean Kessler, RN, BSN, CCRC:  Research Coordinator Lori   Lori Mahon, RN, BSN,CCRC: Research Coordinator Jani  Janie Misfieldt, MA, CCRC:  Research Coordinator Jean Renee Smith, CMA:  Research Coordinator Current Clinical Trials Exhaled Breath Condensate and Nitric Oxide: Non-Invasive Evaluation of Lung Disease after Treatment with Xolair in subjects with Allergic Asthma, 12 years and older. Randomized, Double-Blind, Double-Dummy, Placebo and Active Controlled 5-Way Crossover Study to Assess the Bronchodilatory Action, Safety, Toleration and Pharmacokinetics of Single Oral Doses of PF-04191834 in Asthmatic Patients, 19 years and older. Relationship of RGS2 and RhOA Expression and Airway Hyperresponsiveness, 19 years and older. A 12-week treatment, multi-center, randomized, parallel group, double blind, double dummy study to assess the superiority of indacaterol (150 ug o.d.), 12 years and older. A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Lebrikizumab in Adult Patients with Asthma who are Inadequately Controlled on Inhaled Corticosteroids. A Phase 2b, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous MEDI-528 in Adults with Uncontrolled Asthma, 19-65 years old A 52-week Treatment, Randomized, Double-Blind, Placebo-Controlled, with Open Label Tiotropium, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of NVA237 in Patients with Chronic Obstructive Pulmonary Disease, 19 years and older. A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Ragweed Sublingual Tablet (SCH 39641) in Adult Subjects with a History of Ragweed-Induced Rhinoconjunctivitis with or without Asthma, 19-50 years old.

Home| Team Members | Patient Information |
Current Clinical Trials | Fellowship Program